Reference is made to the subsequent offering of up to 1,500,000 new shares (the "Subsequent Offering") in Hofseth BioCare ASA, and the stock exchange notice issued on 18 September 2019 regarding the result of the Subsequent Offering.

The share capital increase related to the Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises. The share capital has been increased with NOK 1,500,000 through issuance of 1,500,000 new shares, each with a par value of NOK 1. The new share capital is thus NOK 325,820,511 divided by 325,820,511 shares, each with a par value of NOK 1.

For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966

About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that discovers and develops high-value therapeutic medical foods and nutraceutical ingredients from marine resources. HBC has developed a successful research paradigm based on its unique process and marine raw materials, which allows it to rapidly discover and define unique, IP-protected medical co-therapies.

HBC leverages its global relationships with academic and clinical organizations, to help focus and speed-up proof-of-concept discovery studies that drives purposeful, rapid pre-clinical and clinical development.
Several leads are in pre-clinical and clinical development towards co-therapeutic medical foods that will, improve gastro-intestinal (GI) health in various Irritable Bowel Syndromes, help reverse age-related Sarcopenia, reduce the symptoms of asthma and improve hemoglobin status in situationally (iron-deficient) anemic individuals.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh marine resources.
Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, Chicago, Mumbai, Menlo Park and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at and

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act